BioAge Labs, Inc. (BIOA) stock forecast and price target
Price $5.55 · data as of November 13, 2026
12-month price target
Average target$28.89
Upside / downside+420.5%
Analysts9
ConsensusBuy
Low $8.00Average $28.89High $50.00
Gold marker: average target · white marker: today’s price ($5.55)
Analyst ratings
Strong buy 2Buy 5Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.57 | −14.7% | $7M |
| Next fiscal year ends December 31, 2027 | $-2.62 | −2.0% | $15M |
| Next quarter ends December 31, 2026 | $-0.73 | −1.5% | $1M |
| Quarter after ends March 31, 2027 | $-0.69 | −33.2% | $383330 |
Consensus of the analysts covering BioAge Labs, updated daily. In the last 30 days 0 estimates were raised and 2 lowered.
Frequently asked questions
What is the BioAge Labs stock price target?
The average 12-month target from 9 analysts is $28.89, 420.5% above the current price of $5.55 Targets range from $8.00 to $50.00.
Is BioAge Labs a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 5 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is BioAge Labs expected to earn?
Analysts expect EPS of $-2.57 for the fiscal year ending December 31, 2026 and $-2.62 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.